Cellular Biomedicine Group Releases Positive 48-Week Data From Phase I/2a Clinical Trial For Rejoin Treatment Of Knee Osteoarthritis Cellular Biomedicine Group Releases Positive 48-Week Data From Phase I/IIa Clinical Trial for ReJoin Treatment of Knee Osteoarthritis PALO ALTO, Calif., Dec. 5, 2014 -- Cellular Biomedicine Group, Inc. , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today released the 48-week follow-up data analysis of its Phase I/IIa clinical trial for Rejoin human adipose-derived mesenchymal progenitor cell regenerative therapy for Knee Osteoarthritis .
http://ift.tt/12Kek5R
http://ift.tt/12Kek5R
No comments:
Post a Comment